{"id":"W2786168520","doi":"10.1200/jco.2014.32.15_suppl.tps7119","title":"An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dasatinib; Nivolumab; Nilotinib; Tolerability; Internal medicine; Oncology; Myeloid leukemia; Pharmacology; Imatinib; Immunotherapy; Cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001674155,0.002521293,0.002651648,0.0006711042,0.0006086241,0.001142143,0.001186547,0.001944851,0.005305844],"category_scores_gemma":[0.001049887,0.0008922177,0.001335085,0.0005800611,0.001539132,0.001624344,0.0005065169,0.004455531,0.001739692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001738867,"about_ca_system_score_gemma":0.001716097,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001207049,"about_ca_topic_score_gemma":0.003125559,"domain_scores_codex":[0.9993055,0.0002561717,0.0000323642,0.0001671956,0.00007360984,0.0001651753],"domain_scores_gemma":[0.9990578,0.0001277995,0.0001522239,0.00008243739,0.00005050324,0.0005292399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7855679,0.1391624,0.003886544,0.0004559459,0.0007050738,0.0002297275,0.0002881643,0.001670911,0.02987272,0.0002203395,0.002908991,0.03503124],"study_design_scores_gemma":[0.5358171,0.4498133,0.008603155,0.00001531602,0.0002167798,0.0002146138,0.00005487318,0.0007729051,0.002361284,0.0002639728,0.00183254,0.00003410072],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924285,0.001143652,0.0003837638,0.0003765032,0.0001567741,0.002720418,0.001407512,0.00009293503,0.001289988],"genre_scores_gemma":[0.985947,0.001139627,0.001567562,0.001080717,0.0002180371,0.003485863,0.002820323,0.00004390737,0.003696886],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005305844,"threshold_uncertainty_score":0.01774985,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1061647192473671,"score_gpt":0.4579118950979487,"score_spread":0.3517471758505816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}